Arrowhead Mills

Arrowhead Pharmaceuticals is a clinical-stage biotechnology company focused on developing medicines that treat intractable diseases by silencing the genes that cause them. The company utilizes its proprietary Targeted RNAi Molecule (TRiM) platform to create a broad portfolio of RNA interference (RNAi) therapeutics. Its pipeline includes high-potential candidates for liver-targeted diseases like chronic hepatitis B and alpha-1 antitrypsin deficiency, as well as cardiometabolic and pulmonary conditions. Arrowhead has secured strategic collaborations with major pharmaceutical companies, including Takeda and GSK, to accelerate the development and commercialization of its programs. The company is currently advancing several candidates through late-stage clinical trials, aiming to provide transformative treatments for patients with limited options.